Blocking the CD28-B7 T-cell costimulatory pathway abrogates the development of obliterative bronchiolitis in a murine heterotopic airway model

Transplantation

Volumn 69, Issue 5, 2000, Pages 743-749

  Yamada, Akira ^c   Konishi, Katsuhito ^a   Cruz, Georgina Lou E ^c   Takehara, Megumi ^a   Morikawa, Masayuki ^c   Nakagawa, Izumi ^c   Murakami, Masaaki ^c   Abe, Tomio ^c   Todo, Satoru ^a   Uede, Toshimitsu ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

AIRWAY DYNAMICS; ALLOGRAFT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHIOLITIS; GRAFT SURVIVAL; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; T LYMPHOCYTE ACTIVATION; TRACHEA MUCOSA;

EID: 17344386426     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200003150-00012     Document Type: Article

References (29)

1. Reichenspurner H, Girgis R, Robbins R, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg 1995; 60: 1845.
2. Yousem SA, Ray L, Paradis IL, Dauber JA, Griffith BP. Potential role of dendritic cells in bronchiolitis obliterans in heart-lung transplantation. Ann Thorac Surg 1990; 49: 424.
3. Uyama T, Winter JB, Groen G, Wildvuur CR, Monden Y, Prop J. Late airway changes caused by chronic rejection in rat lung allografts. Transplantation 1992; 54: 809.
4. Reismoen NL, Bolman RM, Savik K, Butters K, Herz MI. Are multiple immunopathogenetic events occurring during the development of obliterative bronchiolitis and acute rejection. Transplantation 1993; 55: 1040.
5. Berry GJ, Brunt EM, Chamberlain D, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 593.
6. Hertz HI, Henke CA, Nakhleh RE, et al. Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci USA 1992; 89: 10385.
7. Herz MI, Jessurum J, King MB, Savik SK, Murray JJ. Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol 1993; 142: 1945.
8. Al-Dossari GA, Jessurum J, Bolman RM, et al. Pathogenesis of obliterative bronchiolitis: possible roles of platelet-derived growth factor and basic fibroblast growth factor. Transplantation 1995; 59: 143.
9. Charpin JM, Valcke J, Kettaneh L, Epardearu B, Stern M, Lsrael-Biet D. Peaks of transforming growth factor-β RNA in alveolar cells of lung transplant recipients as an early marker of chronic rejection. Transplantation 1998; 65: 752.
10. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996; 15: 1200.
11. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792.
12. Murakami M, Takahashi Y, Isashi Y, et al. Identification and characterization of an alternative cytotoxic T lymphocyte-associated protein 4 binding molecule on B cells. Proc Natl Acad Sci USA 1996; 93: 7838.
13. Lenshow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4-Ig. Science 1992; 257: 789.
14. Lin H, Boiling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4-Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801.
15. Person TC, Alexander DZ, Winn KJ, Linsley PS, Lowly RP, Larsen CP. Transplantation tolerance induced by CTLA-4Ig. Transplantation 1994; 57: 1701.
16. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177: 165.
17. Yamada A, Murakami M, Ijima K, et al. Long-term acceptance of major histocompatibility complex-mismatched cardiac allograft induced by a low dose of CTLA4IgM plus FK506. Microbiol Immunol 1996; 40: 513.
18. Tarumi K, Murakami M, Yagihashi A, Nakagawa I, Hirata K, Uede T. CTLA4IgG treatment induces long-term acceptance of rat small bowel allografts. Transplantation 1999; 27: 520.
19. Nakagawa I, Murakami M, Ijima K, et al. Persistent and secondary adenovirus-mediated hepatic gene expression using adenovirus vector containing CTLA4IgG. Human Gene Therapy 1998; 9: 1739.
20. Reichenspurner H, Soni V, Mitschke M, et al. Obliterative airway disease after heterotopic tracheal xenotransplantation: pathogenesis and prevention using new immunosuppressive agents. Transplantation 1997; 64: 373.
21. Huang X, Reichenspurner H, Shorthouse R, Morris RE. Heterotopic tracheal allograft transplantation: a new model to study the molecular events causing obliterative airway disease (OAD) in rats. J Heart Lung Transplant 1995; 14: 49.
22. Boehler A, Chamberlain D, Kesten S, Slutsky AS, Liu M, Keshavje S. Lymphocytic airway infiltration as a precursor to fibrous obliteration in a rat model of bronchiolitis obliterans. Transplantation 1997; 64: 311.
23. Gorczynski RM, Chen Z, Zeng H, Fu XM. A role for persisting antigen, antigen presentation, and ICAM-1 in increased renal graft survival after oral or portal vein donor-specific immunization. Transplantation 1998; 66: 339.
24. King MB, Jessurun J, Savik SK, Murray JJ, Hertz M. Cyclosporin reduces development of obliterative bronchiolitis in a murine heterotopic airway model. Transplantation 1997; 63: 528.
25. Cardenas ME, Sanfridson A, Cutler NS, Heitman J. Signal-transduction cascades as targets for therapeutic intervention by natural products. Trends Biotechnol 1998; 16: 427.
26. Ruhlmann A, Nordheim A. Effects of immunosuppressive drugs CsA and FK506 on intracellular signalling and gene expression. Immunobiology 1997; 198; 192.
27. Brazelton TR, Morris ME. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996; 8: 710.
28. Sehgal SN. Rapamune (RAPA, rapamycm, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335.
29. Fahrni JA, Berry GJ, Morris ME. Rosen GP. Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model. Transplantation 1997; 63: 533.